More recently, clinician scientists @Kaufm020 (PMID: 32531207) and @lab_rezvani @may_daher (PMID: 32902645) have validated CISH as a checkpoint in human NK cells and CAR NK cells thus pushing this discovery closer to the clinic to benefit cancer patients
I fondly remember presenting this CISH KO human NK cell data alongside @BioNTech_Group founder Uğur Şahin at the CIMT 2017 in Mainz and the excitement around potential NK cell therapies for cancer.
Having proven the CIS regulates IL-15 signalling in murine NK cells, now @oNKo_innate CEO Jai Rautela deleted CISH in human NK cells in late 2016 and found they too were exquisitely sensitive to IL-15 and had enhanced anti-tumor function https://www.biorxiv.org/content/10.1101/406934v1
With our deep understanding of Natural Killer (NK) cells, we aim to be the first to master NK cell biology and therapeutically harness the cancer-fighting abilities of these remarkable white blood cells.
We are driven by the challenge of engaging the immune system to fight cancer, and focused on delivering the first truly effective NK cell immunotherapies.
